Fresofol 1% MCT/LCT

Fresofol 1% MCT/LCT



Fresenius Kabi


Zuellig Pharma
Concise Prescribing Info
Short-acting IV general anesth for induction & maintenance of general anesth, sedation of artificially ventilated patients in ICU, sedation for surgical & diagnostic procedures alone or in combination w/ local or regional anesth.
Dosage/Direction for Use
Individualized dosage. Induction of anesth Titrate approx 20-40 mg every 10 sec. Adult <55 yr 1.5-2.5 mg/kg body wt, >55 yr & patients w/ ASA grades III & IV Require less (total dose may be reduced to a min of 1 mg/kg body wt) & lower rates (approx 20 mg every 10 sec). Childn >8 yr Approx 2.5 mg/kg body wt. Childn under this age may require higher dose; those w/ ASA grades III & IV require lower dose. Maintenance of anesth Administer as continuous infusion or repeat bolus inj. Adult 4-12 mg/kg body wt/hr, may be reduced to approx 4 kg/body wt/hr during less stressful surgical procedures. May also be given as repeat bolus inj w/ dose increments of 25-50 mg according to clinical requirements. Elderly, patients w/ unstable general condition, impaired cardiac function or hypovolemia & patients of American Society of Anasthesiologist (ASA) grades III & IV Reduce dose according to severity of condition & anesth technique. Childn 9-15 mg/kg body wt/hr, <3 yr May require higher dose. Max duration: 60 min. Sedation during intensive care Adult 0.3-4 mg/kg body wt/hr by continuous infusion. Max: 4 mg/kg body wt/hr. Sedation for diagnostic & surgical procedures Adult 0.5-1 mg/kg body wt over 1-5 min for onset of sedation. Maintenance: 1.5-4.5 mg/kg body wt/hr or supplemented by 10-20 mg bolus infusion for rapid increase of sedation depth. Duration must not exceed 7 days.
Allergy to soya or peanut. Sedation in childn ≤16 yr. Pregnancy & lactation.
Special Precautions
Debilitated, hypovolemic or epileptic patients; patients w/ cardiac, resp, renal or hepatic impairment; disorders of consciousness; disorders of fat metabolism; severely overwt; advanced cardiac failure; high intracranial pressure & low mean arterial pressure. Monitor lipid. Electroconvulsive therapy. May increase risk of relative vagotonia. Do not use dilutions w/ lidocaine soln in patients w/ hereditary acute porphyria. May impair ability to drive or operate machinery. Administration by a target controlled infusion (TCI) system is not advised for induction of general anesth in childn & sedation in ICU. Sedation in patient <16 yr. Not for general anesth in childn <1 mth. Do not administer as rapid bolus inj in elderly.
Adverse Reactions
Hypotension, resp depression, spontaneous movements & myocloni, minimal excitation, bradycardia, tachycardia, hot flushes, hyperventilation, transient apnoea, coughing, singultus. Local pain during initial inj.
Drug Interactions
Concomitant benzodiazepines, parasympatholytics or inhalational anesth may prolong the anesth & reduce resp rate. Opioids & CNS depressants may intensify & prolong sedative effects. Fentanyl may increase blood level. Suxamethonium or neostigmin, cyclosporin.
ATC Classification
N01AX10 - propofol ; Belongs to the class of other general anesthetics.
Fresofol 1% MCT/LCT inj 1 %
(amp) 20 mL x 5 × 1's; (vial) 50 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in